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Abstract
This critical review focuses on the role of steroid hormones and their receptors in the development and treatment of breast 
cancer, with special reference to estrogen receptors, as well as mechanisms of receptor-ligand interactions, response or 
resistance to hormonal therapy against breast cancer, in conjunction with other modalities like surgery and chemotherapy. 
Tamoxifen is used in hormonal treatment of breast cancer for up to five years, depending on the presentation. However, 
there have been recent developments in hormonal therapy of breast cancer in the last ten years, with the introduction of 
many different alternative therapies for this condition. A critical review of published articles in Pubmed/Medline, Athens, 
AJOL, NHS Evidence, Science Direct and Google, relating to hormonal treatment of breast cancer, was undertaken, in 
order to evaluate the mechanisms of estrogen receptor-ligand interactions, their involvement in the etio-pathogenesis 
of breast cancer, resistance of breast cancer cells to anti-hormonal agents, as well as ways of treating breast cancer 
using anti-hormone drugs like tamoxifen. Although tamoxifen is the established drug for hormonal treatment of breast 
cancer, cases of hormone resistance breast cancer have been described recently in the literature. This can happen 
from the beginning, or during treatment. Therefore, we aim to examine the causes of resistance to hormonal treatment 
with a view to understand the options of tackling this problem, and suggest other novel alternative hormonal therapies 
that can be tried, which may overtake tamoxifen in the future. We also seek to emphasize that hormonal therapy has 
a definite place in the treatment of breast cancer along with surgery, chemotherapy and radiotherapy, as the disease 
is often considered to be multi-systemic even from the beginning.
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Introduction
Breast cancer is the most common cancer worldwide, and 
the second leading cause of cancer death.[1] One in nine 
women in the UK and USA will develop the disease in 
their lifetimes. It is more common in Western countries, and 
many factors have been implicated in its etio‑pathogenesis.[2] 
These include age, genetics, family history, diet, alcohol, 
obesity and physical inactivity. Others are endocrine factors 
(both endogenous and exogenous) mammographic density 
and previous benign disease.[3]
The genetic factors implicated include germ‑line mutations 
in high‑penetrance genes such as BRCA1 and 2, P53, 
PTEN (phosphatase and tensin homologue deleted on 
chromosome ten), and over‑expression of HER‑2/neu 
antigen.[4] Both endogenous and exogenous steroid hormones 
such as estrogens and progesterone have been implicated 
in the pathogenesis of breast cancer due to their significant 
effects on cell growth, differentiation and function in the 
breast and other tissues.[4]
Common classes of drugs used for this purpose include the 
selective estrogen receptor modulators (SERMs) typified by 
tamoxifen,[5] selective estrogen receptor down‑regulators 
(SERDs), represented by fulvestrant,[6] aromatase inhibitors 
like aminoglutethimide,[1] and leutinizing hormone releasing 
hormone agonists like buserelin and goserelin.[2] Tamoxifen 
has an established place in both prevention and treatment of 
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breast cancer, but because of its side effects, new generation 
drugs have been introduced, but are yet to replace tamoxifen 
in clinical practice.[1]
Molecular Genetics of Breast Cancer
Five to ten percent of all breast cancers arise from germ‑line 
mutations in high‑penetrance breast cancer susceptibility 
genes such as BRCA1, BRCA2, p53 and PTEN, and confer 
a high individual risk for developing hereditary breast 
cancer.[3] The BRCA1 gene is located on the long arm of 
chromosome 17, while BRCA2 is located on the long arm 
of chromosome 13. Gene‑positive patients have an 80% risk 
of developing breast cancer especially in the pre‑menopausal 
age group.[4]
Aguas et al.,[1] observed that BRCA1 and BRCA2 predispose 
a woman to breast cancer in only 5‑10% of the total number 
of breast cancers and believe that even though family 
history may reflect shared genes, it may also suggest shared 
environmental lifestyle exposures. They therefore advised 
that due to ethical and legal issues, as well as psychological 
consequences, genetic screening should only be carried 
out in the research settings, rather than in routine clinical 
practice. But we know that genetic screening is carried out 
selectively in affected families.
Furthermore, Russell et al.[4] agreed on the presence of 
polymorphisms in breast cancer susceptibility genes with 
low penetrance, which have a greater contribution to breast 
cancer pathogenesis in combination with exogenous factors 
such as diet, alcohol and pollution, as well as endogenous 
factors such as estrogens and progesterone exposures.
This accounts for majority of the sporadic (non‑familial) 
breast cancers which form 90‑95% of all breast cancers 
in women. The familial cancers usually occur in younger 
patients are often multi‑focal or bilateral and have poorer 
prognosis, compared to the sporadic cases which are mostly 
unilateral, occurring in older patients and have better 
outcomes.[3]
The role of HER‑2/neu antigen
This is a growth factor protein which is over‑expressed 
in different types of human cancers, including breast, 
ovarian, lung, gastric, and oral cancers.[7] In 1987, the 
HER‑2/neu proto‑oncogene was revealed to be amplified 
and over‑expressed in 20‑30% of invasive breast cancers, 
and also shown to be associated with poorer outcome and 
shortened survival.[8]
In addition, HER‑2/neu‑positivity is thought to predict the 
likelihood of resistance or sensitivity to some conventional 
hormonal therapies like tamoxifen. Herceptin (trastuzumab), 
a recombinant humanized anti‑HER‑2/neu monoclonal 
antibody, has been shown to improve outcomes for women 
with metastatic breast cancer, either alone or in combination 
with chemotherapy.[9]
Recently, it has been observed that some cases of breast 
cancer are resistant to hormonal therapy (in spite of ER 
positivity) either ab initio or while on treatment, and several 
mechanisms have been postulated to explain these, and 
many strategies are currently being tried to overcome this 
resistance, including the simultaneous use of both herceptin 
(trastuzumab) and tamoxifen to block both the ERs and 
the Her‑2/neu receptor, respectively. However, further 
investigations and clinical trials are necessary before these 
agents become fully established.
Steroid Hormones and their Receptors
Steroid hormones
These include estrogens, progesterone and androgens; they 
are manufactured from one common parent molecule, 
cholesterol via a reaction catalyzed by several enzymes to 
produce a wide variety of hormones for different target 
tissues and organs.[2]
Estrogens have significant effects on growth, differentiation 
and functioning of many tissues such as breast, uterus, 
cardiovascular system, brain and urogenital tract of both 
males and females.[2,6]
Steroid hormone receptors
These are structurally‑related intra‑cellular proteins that 
bind to steroid hormones such as estrogens and progesterone 
and relay their signals leading to down‑stream gene 
expression (signal transduction). Cancers dependent on 
steroid hormones include breast, prostate, testicular, ovarian 
and endometrial cancer which result from deregulation of 
hormone secretion, signaling and receptor action.[10]
Estrogen receptors
Estrogen mediates its functions through two specific 
intra‑cellular receptors estrogen receptor‑ α(ER‑α) and β 
(ER‑β).[2] These, along with androgen receptors (AR), are 
the members of the nuclear hormone receptor superfamily 
which form homo‑dimers and bind specific DNA elements 
called hormone responsive elements (HRE) in the target 
gene promoters.[11]
In Figure 1 A demonstrates the different components 
of the two estrogen receptors, while B demonstrates 
percentage homology of the various receptor parts 
between ER‑α and ER‑β. DBD=DNA‑binding domain, 
LBD=Ligand‑binding domain, TAF 1 and 2=NLS=[2] 
Adapted with kind permission from Elsevier, License 
number 2703630992911
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Mechanism of Estrogen Receptor‑Ligand 
Interaction
On estrogen binding, the receptors undergo a conformational 
change within the ligand‑binding domain (LBD), which 
allows recruitment of co‑activator proteins. Ligand‑bound 
estrogen receptors function directly as transcription factors 
by binding DNA as homo‑dimers to specific sequences 
called estrogen responsive elements (ERE), which contain 
short repeated sequences close to target genes. But, it has 
been found that about one‑third of genes regulated by ERs 
do not contain the ERE‑like sequences and that ER can 
regulate gene expression without binding directly to DNA 
by modulating the function of other transcription factors 
through protein‑protein interactions in the nucleus.[3]
In this way, ERs may function as co‑activator proteins by 
stabilizing DNA binding of other transcription factors or 
by recruiting other co‑activators to these complexes. Apart 
from these nuclear actions of estrogens, there are some 
effects of estradiol which are mediated by an extra‑nuclear 
membrane‑associated ER which is transcribed from 
the same source as the nuclear ER. This non‑genomic 
membrane‑initiated steroid signaling occursacutely with the 
addition of estrogen.[12] The overall effect of this receptor‑ligand 
interaction is to cause significant effects on growth, 
differentiation, and functioning of many tissues which include 
the mammary glands, uterus, bone, cardiovascular system, brain 
and urogenital tract of both sexes. Prolonged and/or excessive 
receptor‑ligand interaction may lead to hyper‑proliferation and 
malignant transformation especially in the breast and uterus.[4]
The estrogen receptor (ER) acts as transcription factor to 
promote cellular responses, but a part of cellular ER also 
associates with membrane in caveolae or caveolae‑related 
lipid rafts on ligand activation. This association may be 
promoted by post‑translational modification of the receptor. 
In these specialized membrane regions, ER may also interact 
with Her‑2 (ligand‑independent activated receptors), by 
association with adaptor proteins, such as Shc or lipid 
raft structural proteins. These receptors may then form a 
signaling complex for signal transduction to MAPK and/or 
AKT kinases, which communicate in turn with nuclear 
ER and steroid receptor co‑activator proteins (SRC) such 
as AIB1. Signaling for cell growth in breast cancer likely 
involves phosphorylation of serine and tyrosine residues 
in nuclear ER and/or SRC proteins [Figure 2].[2] (Adapted 
with kind permission from Elsevier, Licence number 
2703630992911).
Detection of Hormone Receptors
The determination of estrogen receptor (ER) and progesterone 
receptor (PR) status has become routine in breast cancer 
assessment because it has prognostic and therapeutic 
implications. There are many techniques for this purpose, but 
the ligand binding assay (LBA) was initially the most commonly 
used method.[13] In the 1990s immunohistochemical (IHC) 
assays were developed for the assessment of ER/PR status 
because it can be used for small tumors and so assists in 
early diagnosis.[14] A new method called NASBA (nucleic 
acid sequence‑based amplification) was introduced, which 
assesses the mRNA expression of the hormone receptors 
in real time.[13] Further analysis revealed a good agreement 
between NASBA and LBA, and revealed that ER status could 
be predicted using this assay with high sensitivity (72.7%) and 
specificity (93.5%). Lamy et al. therefore suggested that the 
method can be used in conjunction with other commonly 
used methods especially for small tumors.
Hormonal Therapy
A lot of research has been carried out on the mechanism 
of action of steroid hormone receptors, which has helped 
to identify potential molecular targets in cells that could be 
used to prevent or treat breast cancer. However, there is still 
on‑going search for drugs with maximal benefits and minimal 
or absent undesirable effects.[1] In this respect, there are 
different therapeutic approaches for hormone‑dependent 
breast cancer which are discussed below.
Figure 1: Organization and functional domains of estrogen 
receptors
Figure 2: Interaction of growth factor receptor signaling in 
regulating growth of human breast cancers
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Selective Estrogen Receptor Modulators 
These groups of drugs act as receptor binding competitors 
of estrogens and block their effects. The most common and 
successfully used member of this group is tamoxifen, which 
is a non‑steroidal anti‑estrogen that antagonizes the effects 
of estrogens and used in both prevention and treatment of 
breast cancer.[15]
Mechanism of Action of Selective Estrogen 
Receptor Modulators
These drugs serve as anti‑estrogens at the molecular level by 
binding to the ligand binding domain (AF‑2) of the estrogen 
receptor, and because of their different structures, they cause 
a conformational change in the LBD which is different from 
that produced by estrogens.[6] This altered conformation 
prevents the co‑activators from binding to AF‑2, blocking 
the trans‑activation function of the receptors. The AF‑1 
domain remains unaffected and can cause transcriptional 
up‑regulation of the target genes. This is thought to be 
responsible for the partial agonist action of SERMs.[2]
Selective Estrogen Receptor Down‑Regulators 
These are anti‑estrogens with no agonist activity and are 
more potent than SERMs. One of the most widely used 
members is fulvestrant (ICI182780), which is a steroidal 
anti‑estrogen.[6] Fulvestrant is more effective than 
tamoxifen, and has a 100‑fold higher affinity to the ER, with 
no agonist activity in the uterus. It can completely block 
the stimulatory activity of both estrogens and the partial 
agonist activity of the SERMs.[16]
Aromatase Inhibitors
The aromatase inhibitors are superior to tamoxifen in 
both efficacy and toxicity, and have the potential to 
reduce receptor‑negative tumors by synergy with COX‑2 
inhibitors.[1] These drugs block the production of estrogens 
from androgens, which is the main pathway of estrogen 
production in post‑menopausal and non‑pregnant women, 
as well as from other sites and tissues throughout the body.[1] 
Estrogen from these tissues increases the local estrogen level 
and facilitates the pathogenesis of breast cancer. Therefore, 
these drugs block the enzyme involved in estrogen 
biosynthesis (aromatase cytochrome P450 or estrogen 
synthetase), and are commonly used in post‑menopausal 
women.[2] Aminogluthetimide was the first to be used from 
this group, but it is non‑specific and can inhibit estrogen 
synthesis in many other tissues apart from the breast itself, 
with disastrous consequences. Second generation aromatase 
inhibitors (AIs) with higher potency and specificity have 
been introduced and include anastrozole, letozole, and 
exemestane. These have been tried in advanced breast cancer 
with promising results and it is believed that they may replace 
SERMs like tamoxifen which lose their potency with time.[6]
Luteinizing Hormone Releasing Hormone 
Agonists
Luteinizing hormone stimulates the ovaries to produce 
estrogen. GnRH (such as Luteinizing Hormone Releasing 
Hormone (LHRH) causes ovarian ablation by down‑
regulating its own production in the hypothalamus through 
a reversible reaction.[2] These drugs inhibit follicular 
maturation, but not folliculogenesis, and so fertility can 
return following their discontinuation, common examples 
include buserelin, goserelin, leuprolin and triptorelin.
Chemoprevention of Breast Cancer
Current breast cancer research includes the evaluation of drugs 
to reduce the risk of initial clinical development of cancer, and 
in addition to anti‑estrogens commonly used in high‑ risk 
populations; other compounds have also been tried.[1]
Tamoxifen
A report of the National Survey Adjuvant Breast and Bowel 
project (NSABP) which ended in 1997 showed a 49% reduction 
in the incidence of breast cancer in women given 20 mg of 
tamoxifen daily for five years, and estrogen receptor‑positive 
invasive breast cancer decreased by 66%, but there was no 
effect on estrogen receptor negative tumors.[5] However, it is 
important to weigh the risk versus benefits of chemoprevention 
because this drug causes bone fractures and increases the risk 
of endometrial cancer and thrombo‑embolism.[6]
Raloxifene
This is a selective estrogen receptor modulator (SERM) that 
has estrogenic effects on bone and lipids and anti‑estrogenic 
effects on the breast and uterus, and so has been approved 
for the treatment and prevention of post‑menopausal 
osteoporosis.[17] It has been observed that its use for four years 
was associated with a 62% global reduction in breast cancer, 
as well as a 72% reduction in invasive breast cancer.[18,19]
Unlike tamoxifen, raloxifene is not associated with increased 
risk of endometrial cancer.[20,21] and this raises the possibility 
that it may be more useful in chemoprevention than 
tamoxifen.[22]
Aromatase Inhibitors
These are superior to tamoxifen in both efficacy and toxicity, 
and have the potential to reduce receptor negative tumors 
by synergy with COX‑2 inhibitors.[23,24] On‑going trials are 
still testing the efficacy of these drugs not only for adjuvant 
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treatment, but also for primary prevention in women with 
high risk of breast cancer.[24]
Statins
These drugs are used to reduce the level of cholesterol in 
the blood and prevent cardiovascular disease, but also have 
a potential use in cancer management.[25]
Non‑Steroidal Anti‑Inflammatory Drugs
Aspirin and other Non‑Steroidal Anti‑Inflammatory Drugs 
(NSAIDs) have been linked to decreased risk of breast cancer. 
A significant decrease in risk for regular long‑term users of 
aspirin (21%) and other NSAIDs (49%) has been revealed.[26] 
These drugs inhibit cyclo‑oxygenase, the rate‑limiting enzyme 
of prostaglandins which stimulate aromatase gene expression, 
enhancing local estrogen biosynthesis.[27]
Retinoids
These include vitamin A and synthetic analogues which 
facilitate epithelial cell proliferation, but this drug is still 
undergoing clinical trials.[28]
Mechanisms of Resistance to Hormonal 
Therapy
It has been observed that de novo anti‑estrogen resistance 
occurs mainly in ER‑negative/PR‑negative tumors, but 
some studies suggest that cells can sometimes switch phenotype 
from ER‑positive to ER‑negative.[12,29] This may be as a result 
of population remodeling or transcriptional repression of ER 
expression by the tumor cells. Acquired mutations have also 
been noticed to result in dysfunctional forms of ER in the 
laboratories, but rarely observed in the clinics.[12,30]
Also, response to hormonal therapy with tamoxifen has been 
noticed to be of shorter duration in patients with high cyclin 
D1 and over‑expression of this cyclin in breast cancer cells 
leads to acute anti‑estrogen resistance.[31] In addition to 
that, high cyclin E expression has been associated with poor 
relapse‑free survival in patients with endocrine therapies.[32]
Approaches to overcome hormonal resistance
Many strategies are currently being tried to overcome 
hormonal resistance in the treatment of breast cancer.[33] 
One approach is to treat patients with ER‑positive and 
growth factor receptor‑positive tumors simultaneously 
to block both growth factor and ER‑dependent signaling 
pathways which are known to interact and/or synergize in 
promoting tumor growth.[34] Enhanced anti‑tumor effects 
in Her‑2/neu‑over expressing cells with ER are found by 
combined treatment with antibody to Her‑2/neu receptor 
(herceptin) and tamoxifen.[33,35] Combination of herceptin 
with fulvestrant is even more effective in blocking growth 
of breast cancer cells expressing both Her‑2 and ER.[36,37]
These pre‑clinical approaches are currently undergoing 
clinical trials.[38] Growth factor receptor tyrosine kinase 
inhibitors alone or in combination with anti‑hormone agents 
can be used to treat and possibly prevent endocrine‑resistant 
breast cancer.[39,40] in vitro studies have shown that the 
EGFR tyrosine kinase inhibitor Gefitinib (Iressa) suppresses 
proliferation of breast cancer cells in a dose‑dependent 
manner.[41] Shou et al. observed that Gefitinib interferes with 
growth factor receptor and ER cross‑talk and to re‑establish 
co‑repressor complexes with tamoxifen‑bound ER on target 
gene promoters.[42]
Other inhibitors of down‑stream kinases such as P42/P44 
MAP kinase or P38 MAP kinase that are activated with 
tamoxifen resistance may have utility in future.[43] The 
phosphatidylinositol 3‑kinase (PI3K/AKT) pathway 
interferes with ER in breast tumors.[44] A target protein for 
this enzyme is the molecular target of rapamycin (mTOR), 
which can be suppressed using rapamycin analogues.[45] Yu 
et al.[46] have assessed a rapamycin analogue (CCI‑779) in 
pre‑clinical studies and found it to have anti‑tumor efficacy. 
Further clinical trials in combination with aromatase 
inhibitors (AIs) are planned.[47]
Conclusion
The role of steroid hormones and their receptors cannot be 
over‑emphasized in the treatment of breast cancer. Although 
tamoxifen is the traditional anti‑estrogen agent currently 
established in the hormonal treatment of breast cancer, its 
role is increasingly becoming limited due to side effects and 
hormone resistance in some breast cancers. As a result, newer 
agents with better efficacy, no effects on the endometrial 
tissues, and which bypass the problems of hormone resistance 
are being introduced and are likely to overtake or even replace 
tamoxifen in the hormonal treatment of breast cancer, in 
the future. However, further clinical trials will have to be 
carried out before these novel agents can have a definite place 
in the routine management of breast cancer, like tamoxifen.
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